Last reviewed · How we verify

Bupivacaine (Marcaine)

NYU Langone Health · FDA-approved active Small molecule

Bupivacaine blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials to produce local anesthesia.

Bupivacaine blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials to produce local anesthesia. Used for Local infiltration anesthesia, Peripheral nerve blocks, Epidural anesthesia.

At a glance

Generic nameBupivacaine (Marcaine)
SponsorNYU Langone Health
Drug classLocal anesthetic (amide)
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Bupivacaine is a long-acting amide local anesthetic that reversibly inhibits sodium influx into nerve fibers, thereby stabilizing the neuronal membrane and preventing depolarization. This action blocks both sensory and motor nerve conduction in a dose-dependent manner. Its longer duration of action compared to other local anesthetics makes it suitable for both infiltration anesthesia and regional nerve blocks.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: